MET and non-small cell lung carcinoma: In our study, we mainly investigated whether NGS could serve as an alternate method to identify MET amplification status, especially MET amplification, and reported the mutation profiling of the largest cohort of Chinese NSCLC patients with osimertinib resistance to reveal the underlying mechanisms to resistance.